
Current Price | $32.41 | Mkt Cap | $568.2M |
---|---|---|---|
Open | $32.38 | P/E Ratio | 65.70 |
Prev. Close | $32.24 | Div. (Yield) | $0.24 (0.7%) |
Daily Range | $32.26 - $32.93 | Volume | 80,019 |
52-Wk Range | $18.21 - $41.95 | Avg. Daily Vol. | 100,919 |
The Company currently offers four software products for pharmaceutical research: ADMET Predictor/ ADMET Modeler, ClassPharmer, DDDPlus, and GastroPlus.
Current Price | $32.41 | Mkt Cap | $568.2M |
---|---|---|---|
Open | $32.38 | P/E Ratio | 65.70 |
Prev. Close | $32.24 | Div. (Yield) | $0.24 (0.7%) |
Daily Range | $32.26 - $32.93 | Volume | 80,019 |
52-Wk Range | $18.21 - $41.95 | Avg. Daily Vol. | 100,919 |
The best Bull and Bear pitches based on recency and number of recommendations.
Market overestimating the addressable market of their product. Valuation can only be justified if historical growth rates are sustained for a significant period of time, but these growth rates are clearly unsustainble.
Read the most recent pitches from players about SLP.
Recs
drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules
Recs
The company provides simulation software for use in drug development. The FDA uses their software as part of their drug evaluations, and the company is increasing the number of companies and projects that their software is used for. Market leader in the types of simulations they provide.
Recs
nice chart and it pays a small dividend ...
Find the members with the highest scoring picks in SLP.
eversuhoshin (77.20) Score: +1,415.49
The Score Leader is the player with the highest score across all their picks in SLP.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
eversuhoshin | 77.20 | 7/9/2010 |
![]() |
5Y | $1.90 | +1,608.04% | +192.55% | +1,415.49 | 0 Comment | |
marc021248 | < 20 | 7/20/2010 |
![]() |
5Y | $1.97 | +1,545.68% | +194.42% | +1,351.26 | 0 Comment | |
alley11 | < 20 | 7/8/2010 |
![]() |
5Y | $1.99 | +1,525.87% | +192.91% | +1,332.96 | 0 Comment | |
browns31 | < 20 | 7/14/2010 |
![]() |
1Y | $2.00 | +1,519.29% | +186.95% | +1,332.33 | 1 Comment | |
Southoftheborder | 50.41 |
|
![]() |
5Y | $2.10 | +1,445.03% | +151.96% | +1,293.07 | 0 Comment | |
Pepe150 | < 20 | 1/12/2011 |
![]() |
1Y | $2.20 | +1,372.11% | +144.45% | +1,227.66 | 1 Comment | |
stratisticalarb | 97.77 | 5/6/2011 |
![]() |
1Y | $2.35 | +1,276.92% | +133.45% | +1,143.47 | 0 Comment | |
pureoncharts | 48.96 | 1/18/2011 |
![]() |
3W | $2.35 | +1,281.97% | +142.61% | +1,139.36 | 0 Comment | |
kitenio | 93.03 | 11/3/2010 |
![]() |
1Y | $2.46 | +1,218.61% | +162.19% | +1,056.41 | 0 Comment | |
anguijm | 78.56 | 4/25/2011 |
![]() |
5Y | $2.57 | +1,161.19% | +134.45% | +1,026.74 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.